European equities traded in the US as American depositary receipts were treading water late Wednesday morning, edging 0.03% lower to 1,397.50 on the S&P Europe Select ADR Index. From continental ...

Amarin v Hikma. Partner Charles Klein represents Hikma Pharmaceuticals in its dispute with Amarin Pharmaceuticals over Hikma’s generic version of blockbuster heart drug Vascepa. In June 2024, Amarin ...

Appellate courts issued a variety of notable intellectual property (IP) cases in 2024, including cases touching on Orange Book ...

Amarin Pharma v. Hikma Pharmaceuticals 28 & Skinny Labels Holding: The complaint plausibly pleaded induced infringement based on the label and public statements made by the generic manufacturer.

Please provide your email address to receive an email when new articles are posted on . A speaker highlighted key advances in lipid treatment in 2024. Topics included triglyceride and lipoprotein ...

Co-authors reported relationships with Novo Nordisk, the Patient-Centered Outcomes Research Institute, Kowa, Ipsen Pharmaceuticals, NIDDK, Amarin, and Novartis; one co-author reported consulting ...

The U.S. Food and Drug Administration approved a new prescription-strength pain reliever from Vertex Pharmaceuticals on Jan. 30, 2025. Journavx is a non-opioid drug that prevents peripheral nerves ...

LONDON, Feb 4 (Reuters) - Britain's pharmacies regulator on Tuesday tightened rules for online pharmacies' prescribing obesity drugs, ordering them to make changes to prevent people from receiving ...

Rocket Pharmaceuticals (RCKT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising ...

Founded in 1935 by Khwaja Abdul Ahmeid, Cipla operates through two segments: Pharmaceuticals and New Ventures. Cipla Limited specialises in developing medications, primarily treating respiratory ...